Abstract:9693 Background: Cyclooxygenase (COX)-2 inhibitors have been shown to exert antitumor activity against human lung cancer cell lines in vitro, and suppressive effect on lung tumors implanted into recipient mice, but concurrent use of COX-2 inhibitors and antineoplastic agents has not been proven clinically to be superior to chemotherapeutic agent alone. Sequential use of COX-2 inhibitors with chemotherapeutic agent might be a possible treatment option. We initiate in vitro study on the growth-inhibitory effect of inductive, concurrent and sequential celecoxib with cisplatin against A549 cell line to determine the most effective dose and schedule for maximal synergistic cytotoxic effects. We anticipate further appropriate treatment strategies to enhance the cytotoxic effect of chemotherapeutic agents using COX-2 inhibitors in the treatment of lung cancer. Methods: A549 cells were incubated with various concentration and combination of celecoxib and cisplatin for 4 days: celecoxib 24 hours prior to cisplatin as induction, celecoxib simultaneous with cisplatin as concurrent, and celecoxib 24 hours subsequent to cisplatin as sequential treatment. Time of exposure to cisplatin for all combination was 72 hours. Cell viability was determined using MTT assay. Results: The IC50 of cisplatin and celecoxib alone to A549 cell line was 16.64μM/l and 90.42μM/l, respectively. IC50 of cisplatin with celecoxib at 1.55μM/l for induction and concurrent treatment was 23.31μM/l, and 16.52μM/l, respectively, which was not superior to cisplatin alone while that of sequential treatment was 9.98μM/l, which showed synergistic cytotoxic effect against A549 cell line. Conclusions: Sequential celecoxib subsequent to cisplatin exerted the most potent in vitro synergistic cytotoxic effect against lung cancer cells. These may provide a rationale for future clinical trial to evaluate the effect of incorporating COX-2 inhibitors into the cisplatin-based regimen for the treatment of lung cancer. No significant financial relationships to disclose.

Effects of cyclooxygenase-2 inhibitor celecoxib on cyclooxygenase-2 gene expression and cisplatin chemosensitivity in human lung adenocarcinoma A549 cell line

Apoptosis Induced by Celecoxib Eombinated with Cisplatin in Human Osteosarcoma Cell Line MG-63 Via Down-Regulation of PI3K/Akt

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Expression of COX-2 in Primary Ovarian Carcinoma and the Effects of Celecoxib on the Cell Proliferation of the Human Ovarian Carcinoma Cell Line A2780

Effects of COX-2 Inhibitor with Cisplatin on Proliferation and Apoptosis of Pancreatic Cancer Cells

[Effects of Cyclooxygenase-2 Antisense Vector on Proliferation and Sensitivity to Cisplatin of H1299 Cells].

Celecoxib,COX-2 Inhibitor, Inhibited the Proliferation of A549 Human Lung Adenocarcinoma Cells when Combined with Cisplatin

Celecoxib Antagonizes the Cytotoxicity of Cisplatin in Human Esophageal Squamous Cell Carcinoma Cells by Reducing Intracellular Cisplatin Accumulation

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

The in Vitro Synergistic Cytotoxic Effects of Inductive, Concurrent and Sequential Cyclooxygenase-2 Inhibitor with Cisplatin Against A549 Cell Line

Celecoxib Enhanced the Cytotoxic Effect of Cisplatin in Drug-Resistant Human Gastric Cancer Cells by Inhibition of Cyclooxygenase-2.

Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A 2 and peroxisome proliferator-activated receptor gamma

Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner.

Radiosensitization of Celecoxib on Human Lung Adenocarcinoma Cell Line A549 and Inhibition of Migration Ability in Vitro

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Experimental study on inhibitive effect of celecoxib on lung cancer

Experimental Study on Inhibitive Effect of a Non-Steroidal Anti-Inflammatory Drug,celecoxib,on Lung Adenocarcinoma

[Effects of Nonsteroidal Anti-Inflammatory Drug Celecoxib on Expression of Cyclooxygenase-2 (COX-2) in Ovarian Carcinoma Cell].

Effect of Taxotere Combination with Celecoxib on Proliferation of NSCLC Cell

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo.

In Vitro and in Vivo Inhibitory Effect Evaluation of Cyclooxygenase-2 Inhibitors, Antisense Cyclooxygenase-2 Cdna, and Their Combination on the Growth of Human Bladder Cancer Cells.